Navigation Links
The Uptake of Novel Therapies Will Drive the Obesity Drug Market to Increase More than Six-Fold to Over $3.2 Billion in 2018
Date:9/15/2009

WALTHAM, Mass., Sept. 15 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the uptake of novel therapies will drive the obesity drug market to increase more than six-fold, from $512 million in 2008 to more than $3.2 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The new Pharmacor report entitled Obesity finds that the high level of unmet need for efficacious and safe weight-loss therapies will propel the uptake of novel therapies and boost diagnosis and drug-treatment rates of obesity in the world's major pharmaceutical markets. According to the report, physician and patient dissatisfaction with the weight-loss efficacy of current market-leading therapies such as Roche's Xenical, GlaxoSmithKline's OTC Alli and Abbott's Meridia has created an environment that is conducive to the rapid uptake of novel agents. The most notable novel therapies that are expected to launch by 2018 include Arena Pharmaceuticals' lorcaserin and Amylin Pharmaceuticals' pramlintide/leptin combination. The combined sales of lorcaserin and pramlintide/leptin will capture 87 percent of the total obesity market in 2018, according to the report.

The report also finds that the absence of cannabinoid receptor-1 antagonists in the marketplace has created enormous opportunity for drugs with other novel mechanisms of action. Owing to safety concerns, the withdrawal of the cannabinoid-1 receptor antagonist rimonabant (Sanofi-Aventis's Acomplia) from the European markets and the compound's failure to gain U.S. regulatory approval has led several major drug companies to discontinue development of obesity drugs in this class.

"Regulatory agencies and physicians have become increasingly concerned about psychiatric side effects following rimonabant's recent withdrawal from the European market in 2008 because of - among other issues - elevated risk for depression associated with its use," said Decision Resources Therapeutic Area Director Donny Wong, Ph.D. "Previously, regulatory concern had focused on long-term cardiovascular safety following the withdrawal in 1997 of Wyeth's Redux and Pondimin due to cardiac abnormalities associated with these therapies."

The report also finds that although fixed-dose combination agents such as Vivus's Qnexa and Orexigen Therapeutics' Contrave and Empatic are generating some interest among physicians owing to their improved efficacy over currently marketed therapies, most interviewed experts remain concerned about the potential CNS side effects associated with these drugs.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources              Decision Resources, Inc.
    Christopher Comfort             Elizabeth Marshall
    781-296-2597                    781-296-2563
    ccomfort@dresources.com         emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Novel 3-D cell culture model shows selective tumour uptake of nanoparticles
2. Varian and BrainLAB Announce Rapid Uptake of Powerful and Versatile Radiosurgery Platform
3. Uptake of Branded Agents Will Drive the Systemic Lupus Erythematosus Drug Market to Quadruple to $1.4 Billion in 2016
4. Uptake of Next-Generation Antifungals Has Intensified Competition in the Severe Fungal Infections Drug Market
5. 2008 Sees Significant Rise in Prescription Abandonment and Uptake of Generics
6. Frost & Sullivan: Clinical and Cost Benefits to Promote Uptake of Advanced Wound Management Technologies Across Europe
7. The Launch and Uptake of More Than 20 Novel Drugs Over The Next 10 Years Will Drive $12.5 Billion Growth in the Type 2 Diabetes Market
8. Electronic Medical Record Technology Uptake Faces Challenges
9. Generic Erosion of Established Agents Will Offset Growth From Uptake of Emerging Therapies in the Market for Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms
10. Medical Imaging Equipment Finds Significant Uptake in Ghana, Finds Frost & Sullivan
11. Novel virus detection identifies new viruses in study of respiratory infections and asthma attacks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... ... , ... Are You Concerned About Mold In Your Home or Workplace? ... Companies in VA, MD and DC, recently completed its application for the new District ... in the district of Columbia is a good thing stated John Taylor, Owner of ...
(Date:12/2/2016)... ... December 02, 2016 , ... Lori G. Cohen and Sara ... speak at the American Conference Institute’s 21st Drug & Medical Device Litigation Conference ... Sponsor of the conference. , Cohen, who chairs the firm’s Pharmaceutical, Medical Device & ...
(Date:12/2/2016)... Los Angeles, CA (PRWEB) , ... December 02, 2016 , ... For over twenty-four years, ... a lien basis to help personal injury victims find high quality medical care. When ... the Los Angeles area. Fast forward to present day and the now ten-page directory ...
(Date:12/2/2016)... ... December 02, 2016 , ... FlexiSpot, ... of its 60-day free trial program for all of the company’s desktop riser ... a truly hassle free experience. , FlexiSpot’s unique desktop risers use an advanced ...
(Date:12/2/2016)... New York, NY (PRWEB) , ... December 02, 2016 , ... ... Through an exclusive interview with Mediaplanet, Dr. Murthy explains how he was inspired to ... “Early on I learned that medicine is about more than making diagnoses and prescribing ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... -- Seno Medical Instruments, Inc., the company pioneering the development ... the process of diagnosing breast cancer, today announced that ... surveillance and clinical follow-up study at the 2016 ... from December 6-10, 2016 at the Henry B. Gonzalez ... . Seno Medical Instruments will present two ...
(Date:12/5/2016)... and TAIPEI, Taiwan , Dec. ... months of treatment ropeginterferon alfa-2b showed non-inferiority to hydroxyurea (HU) ... a significantly better safety and tolerability profile of ropeginterferon alfa-2b ... from PROUD-PV and the ongoing long-term follow-up trial CONTINUATION-PV to ... PharmaEssentia intends to present this data to the FDA ...
(Date:12/4/2016)... 3, 2016 Sickle cell disease (SCD) is ... blood cells that get stuck in veins and block ... failure, and complications leading to death. Each year, approximately ... and most of them lack access to comprehensive care ... long-term therapy for SCD, a pill called hydroxyurea approved ...
Breaking Medicine Technology: